Dl-3-n-Butylphthalide (NBP) ：A Promising Therapeutic Agent for Ischemic Stroke.

Dl-3-n-Butylphthalide (NBP)：A Promising Therapeutic Agent for Ischemic Stroke. CNS Neurol Disord Drug Targets. 2018 Jun 12;: Authors: Wang S, Ma F, Huang LJ, Zhang Y, Peng YC, Xing CH, Feng YP, Wang XL, Peng Y Abstract Stroke is a leading cause of morbidity and mortality in both developed and developing countries all over the world. The only drug for ischemic stroke approved by FDA is recombinant tissue plasminogen activator (rtPA). However, only 2-5% stroke patients receive rtPAs treatment due to its strict therapeutic time window. As ischemic stroke is a complex disease involving in multiple mechanisms, medications with multi-targets may be more powerful compared with single-target drugs. Dl-3-n-Butylphthalide (NBP) is a synthetic compound based on l-3-n-Butylphthalide that is isolated from seeds of Apium graveolens. The racemic 3-n-butylphthalide (dl-NBP) was approved by Food and Drug Administration of China for treatment of ischemic stroke in 2002. A number of clinical studies indicated that NBP not only improved the symptoms of ischemic stroke, but also contributed to the long-term recovery. The potential mechanisms of NBP for ischemic stroke treatment may target different pathophysiological processes, including anti-oxidant, anti-inflammation, anti-apoptosis, anti-thrombosis, and protection of mitochondria et al. In this review, we have summarized the research progress of NBP for the treatment of ischemic stroke during the pa...
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Tags: CNS Neurol Disord Drug Targets Source Type: research